Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease

April 30, 2024 updated by: samar salah eldin abdelrahman, Assiut University
  1. To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients
  2. Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease
  3. Compare serum ADAM 17 and Caspase 3 levels in Diabetic Chronic kidney disease patients and Non Diabetic Chronic kidney disease patients

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Kidney diseases represent a global public health problem ,It is estimated that 10-15% of the population is affected by Chronic kidney disease.(1) Chronic kidney disease (CKD) is defined by persistent urine and structural abnormalities or impaired excretory renal function ( an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2, persisting for three months or more suggestive of a loss of functional nephrons) (2) the most common contributing factors to CKD include genetic abnormalities and ageing, while the most common underlying diseases associated with CKD are diabetes and hypertension However, CKD can be also due to infectious diseases, autoimmune diseases (such as lupus), and medications (3) A disintegrin and metalloproteinase (ADAM) 17, also known as tumour necrosis factor α-converting enzyme (TACE), is a metalloproteinase that releases the ectodomains of most growth factors, cytokines, receptors and enzymes and has been associated with the presence of chronic kidney disease (5) Clinical and experimental studies have shown that ADAM17 is involved in chronic kidney disease (CKD) with a proinflammatory and profibrotic role, suggesting that it could be an important mediator of CKD progression. ADAM17 inhibition attenuates fibrosis and inflammation, suggesting that its inhibition may be a possible new valuable therapeutic tool in fibrotic kidney disease treatment(6) Caspases (cysteine aspartases, cysteine-aspartic proteases) are protease enzymes which play a role in apoptotic pathway. Their name derives from their specific cysteine protease activity . Most cells have caspases in an inactive proenzyme form, which is activated and induces other pro-caspases, thus initiating a protease cascade. This process is able to amplify the apoptotic signaling pathway and to induce rapid cell death, ,Caspase-3 plays a dominant role in apoptosis, involved in the pathogenesis and progression of chronic kidney disease (CKD).(7)

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Patients with chronic kidney disease with different contributing factors e.g Diabetis mellitus , Hypertension,autoimmune diseases.

Description

Inclusion Criteria:

  1. Patients with chronic kidney disease
  2. Patients with different contributing factors e.g Diabetis mellitus, Hypertension ,autoimmune diseases.

Exclusion Criteria:

  1. Patients with pulmonary oedema or hepatic disease .
  2. Patients with known any organ malignancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
-Group (6) :control Group
apparently healthy individuals with matched age and sex are included in this study as a control group for comparison
Other: caspase 3 and ADAM 17 biomarkers
Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
- Group (1): stage(1) CKD patient group
Stage 1 of CKD (eGFR of 90 or greater)
Other: caspase 3 and ADAM 17 biomarkers
Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
-Group (2): stage (2) CKD patient group
Stage 2 of CKD (eGFR between 60 and 89)
Other: caspase 3 and ADAM 17 biomarkers
Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
-Group (3) :stage(3) CKD patient group
Stage 3 of CKD (eGFR between 30 and 59)
Other: caspase 3 and ADAM 17 biomarkers
Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
-Group (4) :stage (4) CKD patient group
Stage 4 of CKD (eGFR between 15 and 29)
Other: caspase 3 and ADAM 17 biomarkers
Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
-Group (5):stage(5) CKD patient group
Stage 5 of CKD (eGFR less than 15)
Other: caspase 3 and ADAM 17 biomarkers
Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients
Time Frame: baseline
Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Principal Investigator: samar salah, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 26, 2024

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

October 31, 2027

Study Registration Dates

First Submitted

April 26, 2024

First Submitted That Met QC Criteria

April 26, 2024

First Posted (Actual)

April 30, 2024

Study Record Updates

Last Update Posted (Actual)

May 1, 2024

Last Update Submitted That Met QC Criteria

April 30, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • caspase 3 and ADAM 17 in CKD

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Diseases

Clinical Trials on caspase 3 and ADAM 17 biomarkers

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe